Oncogenic Partnerships: EWS-FLI1 Protein Interactions Initiate Key Pathways of Ewing's Sarcoma
Document Type
Article
Publication Date
2010
Digital Object Identifier (DOI)
https://doi.org/10.1158/1078-0432.CCR-09-2261
Abstract
Targeted therapy for cancer, which is specifically directed toward the cancer without any potential for effects outside of controlling the tumor, is a gold standard for treatment. Ewing's sarcoma contains the potential target EWS-FLI1, as a result of a pathognomonic chromosomal translocation. The EWS-FLI1 fusion protein includes the EWS domain, a potent transcriptional activator alongside the highly conserved FLI1 ets DNA-binding domain. Because of the combination of these domains, the EWS-FLI1 fusion protein acts as an aberrant transcription factor whose expression results in cellular transformation. EWS-FLI1 functions by binding to normal cellular protein partners in transcription and splicing, similar to how a virus would corrupt normal cellular machinery for virion production. Therefore, understanding the protein-protein interactions of EWS-FLI1 and the pathways that are regulated by these partnerships will inform both oncogenesis and therapeutics. This review describes the known protein partners and transcriptional targets of EWS-FLI1, while proposing strategies for exploiting these partnerships with targeted therapy. Clin Cancer Res; 16(16); 4077–83. ©2010 AACR.
Was this content written or created while at USF?
Yes
Citation / Publisher Attribution
Clinical Cancer Research, v. 16, issue 16, p. 4077-4083
Scholar Commons Citation
Erkizan, Hayriye V.; Uversky, Vladimir N.; and Toretsky, Jeffrey A., "Oncogenic Partnerships: EWS-FLI1 Protein Interactions Initiate Key Pathways of Ewing's Sarcoma" (2010). Molecular Medicine Faculty Publications. 469.
https://digitalcommons.usf.edu/mme_facpub/469
